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Glycolipid phase behaviour is less well understood than for many phospholipids, but due to their structural
and functional diversity, glycolipids represent an important group of amphiphiles from which biological
function is derived. Here we have incorporated a synthetic glycolipid in binary mixtures with DOPC (1,2-
dioleoyl-sn-glycero-3-phosphocholine) into giant unilamellar vesicles (GUVs) at biologically relevant
concentrations and observed the phase behaviour of the lipid mixtures for a range of glycolipid
concentrations. At low concentrations, the glycolipid is fully dispersed in the GUV membrane. At
glycolipid molar concentrations above 10%, the formation of lipid tubules is observed, and is consistent
with the formation of a columnar lipid phase. Lipid tubules are observed in aqueous and oil solvents,
suggesting that both hexagonal and inverted hexagonal lipid arrangements can be formed. This work
may offer insights into the biological function of glycolipids and the challenges in formulating them for
use in industrial applications.Introduction
Glycolipids are of signicant biological importance due to their
function in cell adhesion, recognition, signalling and differen-
tiation.1–3 There are several classes of glycolipids, including
glycoglycerolipids, glycophosphatidylinositols and glyco-
sphingolipids.4 Glycolipids, like other amphiphiles can adopt
different self assembled structures, including lamellar, hexag-
onal or cubic phases, depending on the thermodynamic
conditions.5 The phase behaviours for a range of lipids and their
mixtures have been explored over many decades.6–10 The phase
behaviour for lipids is affected by the structure of the head- and
tail-groups, the balance of the attractive and repulsive forces
exerted by the chain and headgroups respectively, as well as the
interactions between the neighbouring carbohydrate head-
groups and hydration conditions.
Glycolipids have been shown to play a role inmaintenance of
membrane integrity,11,12 photosynthesis,13 certain aspects of
energy transduction14 or binding and transfection of viruses.15,16
Phase behaviour and phase morphology for glyceroglycolipids
have been previously studied.17–19 They have been shown to
adopt a variety of geometries, including lamellar gel (Lb),
lamellar liquid crystalline (La), inverted cubic (QII) and hexag-
onal (HI and HII) phases. The conditions required for transi-
tions between these phases are inuenced by the structure andsity of Ireland Maynooth, Maynooth Co.
nuim.ie
tion (ESI) available. See DOI:
3length of the carbon chain. The structure of the headgroup,
mainly the conguration of the anomeric carbon as well as the
number of sugar residues in the headgroup also inuences the
phase behaviour.19,20 When incorporated into vesicles, glyco-
lipid molecules may be used to study the phase behaviour
within model membranes.21,22
Due to the structural and functional diversity of naturally
occurring and synthetic glycolipids, they are widely used in a
range of academic and industrial applications. Glycolipid-based
probes, containing a uorophore or other type of tag, have been
developed to study cell signalling and response, cellular uptake
and trafficking.23
The specicity of carbohydrate interactions is of interest for
targeted delivery. This is usually achieved by glycolipid-bearing
liposomes containing for example, antigens necessary for
immune system activation;24 a variety of drugs against inam-
mation25 or as cancer therapies.26 The glycolipid headgroup
provides the chemical moiety for targeted delivery. Sialyated
Lewis antigens bind to selectin receptors present on the surface
of endothelial cells, platelets and leukocytes and are widely
studied due to their potential therapeutic application in facili-
tating delivery for inammatory disease.27–29 There is also a
growing interest in the role of glycolipids in bacterial and viral
infection and therefore the potential for glycolipid-based ther-
apeutic strategies.30–33
Here we present experiments demonstrating a protected
synthetic glycolipid, with a galactose-based headgroup and two
asymmetrical hydrocarbon tails, has been successfully incor-
porated into phospholipid–cholesterol giant unilamellar vesi-
cles (GUVs) at biologically relevant concentrations. TheThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineglycolipid-containing liposomes show good stability at room
temperature. The synthetic glycolipid also shows interesting
concentration-dependent phase behaviour in binary mixtures
with DOPC and in ternary mixtures with DOPC and cholesterol,
which will also be discussed. Here we use an acetylated
synthetic glycolipid to demonstrate that these synthetically
accessible lipid structures may be used as glycolipid mimics
without the difficulties associated with purication of naturally
occurring forms. The use of synthetic glycolipids offers the
opportunity for further functionalization or modication aer
formation of self assembled structures, as demonstrated
recently.34Experimental
Materials
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1-myr-
istoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]-dodecanoyl]-
sn-glycero-3-phosphocholine (NBD-PC) (both highly puried) were
purchased from Avanti Polar Lipids (Alabaster, Alabama).
Cholesterol (highly puried) was purchased from Calbiochem,
Merck (Darmstadt, Germany). Chloroform (analytical reagent
grade) (Acros Organics), and Pt-metal wires (99.9%) were
purchased from Fisher Scientic (Ireland). Methanol (HPLC
reagent grade), and mineral oil were purchased from Sigma
Aldrich. Ethanol (HPLC reagent grade) was purchased from
Lennox (Ireland). Imaging Spacer Secure-Seal™ and Perfusion
Chamber Cover Well™ were purchased from GRACE Bio-Labs
(Bend, Oregon). D-(+)-Saccharose was purchased from VWR
International. N-(4,4-Diuoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-pentanoyl) sphingosine (bodipy FL C5 ceramide),
cholesteryl 4,4-diuoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-inda-
cene-3-dodecanoate (cholesteryl bodipy FL C12), N-((4-(4,4-
diuoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl) phe-
noxy) acetyl sphingosine (bodipy TR ceramide) (highly puried)
were purchased from Invitrogen (Carlsbad, CA).
The synthesis of the glycolipid used in these experiments has
been described previously.35Fig. 1 Fluorescent microscopy images of GUVs containing 1 : 1 : 1
DOPC–cholesterol–sphingomyelin (label is 0.05% cholesteryl bodipy
FL C12).GUV preparation
W/O emulsion method (Method 1). A protocol based on the
method of Noireaux and Libchaber36 was used. A lipid mixture
of the desired lipid composition was dissolved in mineral oil at
a concentration of 5 mg ml1. The mixture was then heated and
sonicated at 50 C for 1 hour and incubated overnight at room
temperature. 200 ml of the clear supernatant and 1–1.5 ml of PBS
buffer were vortexed for a few seconds to form a water-in-oil
emulsion. Aer leaving the emulsion to rest for a few minutes,
50 ml of the emulsion was placed on top of PBS buffer (950 ml)
and centrifuged at 2000 rpm for 1 hour to form GUVs.
Hydration method (Method 2). A previously described
method was used;37 20 ml of lipid of the required composition,
dissolved in chloroform (0.1 M) was placed in a pear-shaped
ask. 180 ml of chloroform was added. Excess chloroform was
removed by evaporation, forming a thin layer of lipid on the
inner surface of the ask. The ask was then placed underThis journal is © The Royal Society of Chemistry 2014vacuum for 24 hours to remove remaining chloroform. Nitrogen
gas was passed through MilliQ water at 50 C and then onto the
dried lipid lm for 40 minutes. Enough sucrose solution (0.1 M)
was added to the ask to cover the lipid lm. The ask was
sealed and placed in an oven at 50 C for 24 hours.
Rapid hydration method (Method 3). A protocol published
by Moscho38 was modied slightly as follows; 20 ml of lipid of
the required composition, dissolved in chloroform (0.1 M) was
placed in a pear-shaped ask. 150 ml of ethanol and 900 ml of
chloroform were added. Milli-Q water (7 ml) was added to the
ask along the inside wall and the organic phase was removed
using a rotary evaporator at temperature ca. 40 C.Imaging GUVs and size measurement
Giant unilamellar vesicles were observed using an Olympus
BX61 microscope, equipped with a digital imaging system, at
either 60 or 100 magnication. Images of the structures
formed were viewed and recorded using CellF soware. For
uorescence microscopy, a mercury lamp was used for excita-
tion and images were viewed using band pass FITC or long pass
Cy5 lter. All image analysis was done using ImageJ39 and Fig-
ureJ soware.40Results and discussion
The phase behaviour of model membranes composed of a
variety of lipid and cholesterol mixtures have been extensively
studied.41–45 The presence of coexisting lamellar gel (Lb) and
liquid-crystalline (La) phases was previously shown for ternary
lipid mixtures containing DOPC, cholesterol and DPPC or
sphingomyelin (SM). In fact, only small differences were
observed between phase diagrams of DOPC–cholesterol–DPPC
and DOPC–cholesterol–SM.46,47 We have prepared 1 : 1 : 1
DOPC–cholesterol–SM lipid mixtures and have observed coex-
isting liquid phases (Fig. 1), as previously described.47
We are using a synthetic glycolipid molecule in which pro-
tecting groups are present instead of the –OH groups of a
naturally occurring lipid. It has a exible linker and two asym-
metric hydrocarbon tails (Fig. 2). The synthesis for this glyco-
lipid has been described previously.35 Our initial objective wasSoft Matter, 2014, 10, 3978–3983 | 3979
Fig. 2 Chemical structures of the synthetic glycolipid (A), sphingo-
myelin (B), bodipy FL C5 ceramide (C), bodipy TR ceramide (D) and
cholesterol bodipy FL C12 (E).
Fig. 3 Clusters of GUVs containing glycolipid formed by Method 2,
composed of 1 : 9 glycolipid–phospholipid mixtures.
Fig. 4 Optical microscopy images of tubular structures observed in
binary mixtures of DOPC–glycolipid. Left panel; phase contrast,
middle panel; polarization; right panel, fluorescence due to labelled
glycolipid.
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View Article Onlineto show that it is possible to form GUVs containing this
synthetic glycolipid, at biologically relevant concentrations and
to investigate if liquid phase separation is observed within the
membranes containing the protected form of the glycolipid.
A lipid lm consisting of only the synthetic glycolipid (100%)
does not swell aer hydration and therefore does not produce
vesicles. The membranes we describe here contained binary
mixtures of glycolipid (A) and DOPC or ternary mixtures of
DOPC–glycolipid–cholesterol. The incorporation of glycolipid A
into GUVs was possible using all of the methods we tried. In all
experiments described here, a uorescently labelled lipid was
incorporated at a concentration of 0.05%, 0.1% or 1%
(depending on the dye used).
In order to observe the membrane containing our synthetic
glycolipid, we used either bodipy FL C5 ceramide (C) or bodipy
TR ceramide (D) (Fig. 2). In glycolipid–DOPC binary mixtures in
the absence of cholesterol and with glycolipid concentrations
from 1–5 mol%, the glycolipid appears to be fully incorporated
into the GUVs and no phase separation is observed. The pres-
ence of the labelled lipid in the vesicle is in itself not conr-
mation of the inclusion of the glycolipid in the GUV. However,
the vesicles formed with the inclusion of glycolipid exhibit
properties not present for vesicles formed in its absence. GUVs
containing glycolipid tend to cluster into chains and groups3980 | Soft Matter, 2014, 10, 3978–3983(Fig. 3). Narrower size distributions for vesicles containing
glycolipid are also observed (Fig. S1†). Aer swelling of the lipid
lm, no residual material is observed, and thus we believe that
up to 5% glycolipid, the synthetic lipid is fully incorporated into
the GUVs.
The vesicles formed are in high yield and rather stable. We
observed no changes in the shape or stability of the vesicles for
up to 12 days (stored at room temperature) which is longer than
for vesicles formed without the synthetic glycolipid. This may be
due to hydrogen bonding interactions, which alter the polarity
of the lipid headgroup as suggested recently.48 This increase in
stability led to a decrease in the CVC (critical vesicle concen-
tration) of a fatty acid membrane containing a glycolipid.48
As the concentration of glycolipid is increased from 5 to
10%, we observe the formation of tubular structures with
increasing abundance as the concentration of glycolipid
increases (Fig. 4). At glycolipid concentrations from 10–30%,
the tubular structures co-exist with GUVs. It appears that the
90 : 10 DOPC–glycolipid composition at which the tubular
structures appear, represents the maximum solubility of the
synthetic glycolipid within the phospholipid in the lamellar
phase. We observed the formation of the tubular structures in
the presence and absence of uorescent dyes, which eliminates
the dyes as a reason for tubule formation (Fig. S2†).
To test if our chosen uorescent label (bodipy FL C5
ceramide) was possibly masking any phase separation within
the lipid lamellar phase, we used a second dye, cholesteryl
bodipy FL C12, which partitions into the liquid ordered phase
(Lo), oen called a lipid ‘ra’, which would allow us to observe
liquid phase separation if the bodipy ceramide dyes failed to do
so.49 In both cases, no liquid phase separation was observed. We
do not expect DOPC or DOPC–cholesterol to form these types of
structures in the absence of the glycolipid.50,51 To be absolutelyThis journal is © The Royal Society of Chemistry 2014
Fig. 6 Fluorescent microscopy images of tubules formed in aqueous
solvent (A) and in mineral oil (B); lipid compositions are: 1 : 9 (A) and
1 : 4 (B) glycolipid–DOPC labelled with 0.1% bodipy FL C5 ceramide.
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View Article Onlinecertain that liquid phase separation does not occur, we per-
formed two-dye experiments (Fig. 5).
We prepared GUVs using an initial glycolipid concentration
of 33 mol%, which is above the solubility of the glycolipid
within the lamellar phase to ensure oversaturation. In these
experiments, the glycolipid dye (bodipy FL C5 ceramide or
bodipy TR ceramide) was used with either cholesteryl bodipy FL
or NBD PC.52 That is, we created a glycolipid–cholesterol two-
dye pair and a glycolipid–phospholipid two-dye pair to ensure
that phase separation of the glycolipid from either the phos-
pholipid or cholesterol was not occurring. No phase separation
was observed in either case.
We also investigated if cholesterol could contribute to the
formation of a liquid ordered, Lo phase in the glycolipid con-
taining membranes. We formed membranes with a xed
glycolipid concentration of 5% and varied the DOPC–choles-
terol ratio so that the concentration of cholesterol varied from
10–30%. With increasing cholesterol content, there is a lower
yield of vesicles formed and a decrease in their size, most
apparent at 30% cholesterol (Fig. S3†). However we did not
observe coexistence of liquid-ordered and liquid-crystalline
phases in the bilayers formed over the range of cholesterol
concentrations used.
To ensure that the tubules formed are not artefacts of the
preparation method selected, we prepared vesicles in a number
of ways (Methods 1–3, Experimental). Methods 2 and 3 produce
the same self-assembled structures at the same glycolipid
concentrations (both GUVs and tubules at glycolipid concen-
trations above 10%).
The emulsion based method (Method 1) shows slightly
different behaviour. GUVs containing glycolipid are observed in
the aqueous phase. Interestingly however the tubular structures
that are observed in the aqueous phase for the hydration
methods (Fig. 6A) are found inside the mineral oil droplets that
occur in the emulsion method (Fig. 6B). The lipid tubules are
optically birefringent indicating that the structures are ordered
and not just aggregated material (Fig. 4 (middle panel)).Fig. 5 Fluorescent microscopy images of GUVs (1 : 1 : 1 DOPC–
glycolipid–cholesterol) prepared by Method 2. (A–C) Labelled with
0.05% cholesteryl bodipy FL C12 and 0.05% bodipy TR ceramide; (D–F)
labelled with 0.05% bodipy TR ceramide 1% NBD-PC; (C & F) overlay of
the two images.
This journal is © The Royal Society of Chemistry 2014Taken together, this behaviour is consistent with the
formation of a columnar phase with hexagonally packed lipid
tubules in the aqueous solvent and inverted hexagonally packed
tubules in the mineral oil droplets. Given the sizes of the
tubular features we see, each tubular structure would represent
several layers of hexagonally arranged lipid tubes.
The formation of a non-lamellar phase is driven by a curva-
ture stress on the membrane which is induced in the presence
of the glycolipid. The tendency of lipid membranes to arrange
themselves in specic phases may be qualitatively described by
the Israelachvili–Mitchell–Ninham packing parameter, P ¼ v/al,
where v is the molecular volume, a is the cross-sectional area of
the headgroup and l is the length of themolecule.53We presume
that up to a molar concentration of 5%, the glycolipid is fully
dispersed within the DOPC lamellar phase in the GUVs as
indicated earlier. We only observe tubular structures at molar
concentrations of 10%, which suggests that if the glycolipid is
dispersed equally between the lamellar and hexagonal phases
that a minimum of 5% glycolipid is required for the formation
of a hexagonal phase. In reality, we do not know if there is an
equal distribution of glycolipid between the two phases.
Lamellar phases are favoured at P values close to 1.53 The
glycolipid has both a larger cross-sectional area of the head-
group, a, due to the bulky sugar and a smaller molecular
volume, v, than DOPC in the aqueous phase due to its asym-
metric tails. With increasing glycolipid concentrations this will
result in a value of P < 1 and hence the formation of a hexagonal
phase. The value of P should exceed 1 for the formation of an
inverted hexagonal phase. The inverted hexagonal phase forms
in a mineral oil solvent for this system, hence the values for a, v
and l for the same lipid will change due to the different solvent
environment. In this system, a reorientation of the lipid head-
group towards the lipid tails, is plausible due to the exible
linker and would result in a decrease in the values of both a and
l and lead to a packing parameter, P > 1.
Both HI and HII phases have been observed for glycolipids
previously.17,54,55 Hence, there appears to be a transition from a
La lipid phase in the GUVs to a columnar HI or HII lipid phase at
a glycolipid concentrations between 5 and 10%, depending on
whether the tubules are in an aqueous or mineral oil solvent.
The proposed arrangement of the columnar phase is illustrated
in Fig. 7.Soft Matter, 2014, 10, 3978–3983 | 3981
Fig. 7 Arrangement of lipids in columnar phases; (A) inverted hexag-
onal (HII) arrangement of lipids in which the glycolipid tail groups are
oriented towards the mineral oil solvent and (B) hexagonal (HI) lipid
packing, where the glycolipid headgroup is oriented towards the
aqueous solvent. We believe the lipid layers are composed of glyco-
lipid–phospholipid mixtures.
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View Article OnlineGiven that our synthetic glycolipid has a slightly hydro-
phobic headgroup, we have considered the possibility that a HII
phase forms, even in aqueous solvent. However, the hydro-
carbon tails are sufficiently long, that a HII phase in aqueous
solvent would be entropically unfavourable and a HI phase is
more likely. Further work will be required to conrm both the
proposed structures and specic lipid arrangements in both
aqueous and oil solvents.
We have conrmed that for the hydration methods used to
form the GUVs that the lipid is fully dispersed with the DOPC
and cholesterol in chloroform before vesicle formation and that
the structures observed are not due to insolubility. We believe
that the columnar phase is composed of both glycolipid and
phospholipid, since the glycolipid does not by itself swell into
an aqueous phase.
Since the uorescent images show uniform distribution of
the uorescent dye, we assume that the lipid composition in theFig. 8 Fluorescent images of GUVs attached to the surface of the
mineral oil droplet; (A–C) 80 : 20 DOPC–glycolipid (0.1% bodipy FL C5
ceramide 1% NBD-PC); (D) fluorescent intensity profile (cross-section
intensity).
3982 | Soft Matter, 2014, 10, 3978–3983tubules is homogeneous. When GUVs are formed by Method 1,
several of them are found on the surface of mineral oil droplets.
In order to analyse the lipid distribution on the surface of the
mineral oil and to ensure that the glycolipid does not partition
preferentially into the mineral oil solvent we performed uo-
rescent microscopy with two uorescent dyes, bodipy TR
ceramide and NBD-PC, known to partition into a phospholipid
rich phase. Our choice of 20% glycolipid content was again
dictated by the need to saturate the mineral oil, used in the rst
step of the preparation method.
As shown in Fig. 8 the two uorescent lipids are localized in
the same areas on the surface of the oil droplet and no phase
separation of the synthetic glycolipid is induced on the surface
of the mineral oil. This may also provide further evidence that
both the glycolipid and phospholipid are required for tubule
formation, since the vesicles on the mineral oil droplets are the
likely source of material for the columnar phase to form.
Conclusions
A protected synthetic glycolipid has been incorporated into GUV
membranes by a variety of methods at biologically relevant
concentrations in binary mixtures with DOPC and in ternary
mixtures with DOPC and cholesterol. In both cases, the glyco-
lipid is fully dispersed in the lamellar phase and no liquid phase
separation was observed in the range of concentrations where
the glycolipid was soluble in the vesicle membrane. At glyco-
lipid concentrations above 10%, the formation of lipid tubules
occurs, which we believe is most likely a hexagonally packed
columnar lipid phase. The tubules are optically birefringent and
occur both in aqueous solvent and in mineral oil droplets
formed during GUV preparation by an emulsion based method.
The study of the phase behaviour of both naturally occurring
and synthetic glycolipids is important in understanding their
role in biological processes. The effect of total lipid concentra-
tion on the aggregate structure has not been examined, but will
be important to investigate in future work. The phase behaviour
of glycolipids in mixtures with other membrane forming lipids
has yet to be fully explored and this work is a contribution to
this effort.
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